G-Protein Coupled Receptor (GPCR) Agonist - Pipeline Insight, 2022
US$ 1,250.00
... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “G-Protein Coupled Receptor (GPCR) Agonist The report ...
January 2022
60 pages
Growth Hormone (GH) Agonist - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Growth Hormone (GH) Agonist The report assesses ...
January 2022
60 pages
Growth Hormone Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Growth Hormone Antagonist The report assesses ...
January 2022
60 pages
Guanylate Cyclase-Coupled Receptor Activators - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Guanylate Cyclase-Coupled Receptor Activators The ...
January 2022
60 pages
H Antagonist - Pipeline Insight, 2022
US$ 2,000.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “H Antagonist The report assesses the active H Antagonist pipeline ...
January 2022
120 pages
H 2 Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... 2 Antagonist - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent ...
January 2022
60 pages
H 3 Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... 3 Antagonist - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent ...
January 2022
60 pages
H 4 Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... 4 Antagonist - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent ...
January 2022
60 pages
Histone deacetylase (HDAC) Inhibitors- Pipeline Insight, 2022
US$ 2,500.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “HDAC Inhibitor The report assesses the active HDAC Inhibitor ...
January 2022
150 pages
Heat shock protein inhibitors - Pipeline Insight, 2022
US$ 1,500.00
... (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Heat Shock Protein (Hsp) Inhibitor The report ...
January 2022
60 pages
Hedgehog Signaling Pathway Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Hedgehog Signaling Pathway Antagonist The report ...
January 2022
60 pages
Hepatitis C Virus (HCV) Protease Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Hepatitis C Virus (HCV) Protease Inhibitor The report ...
January 2022
60 pages
Hepcidin Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Hepcidin Antagonist The report assesses ...
January 2022
60 pages
HIF-1 Alpha Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “HIF-1 Alpha Inhibitor The report assesses the active HIF-1 Alpha ...
January 2022
60 pages
HIV Attachment Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “HIV Attachment Inhibitor The report assesses ...
January 2022
60 pages
Hypoxia Inducible Factor 1 (HIF-1) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Hypoxia Inducible Factor 1 (HIF-1) Inhibitor The report ...
January 2022
60 pages
IkappaB Kinase (IKK) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “IkappaB Kinase (IKK) Inhibitor The report assesses ...
January 2022
60 pages
IL-6 Receptor Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “IL-6 Receptor Antagonist The report assesses ...
January 2022
60 pages
Inducible Nitric Oxide Synthase (iNOS or Type II NOS) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Inducible Nitric Oxide Synthase (iNOS or Type II NOS) Inhibitor ...
January 2022
60 pages
Inhibitor of Apoptosis (IAP) Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Inhibitor of Apoptosis (IAP) Antagonist The report ...
January 2022
60 pages
Insulin Like Growth Factor (IGF) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Insulin Like Growth Factor (IGF) Inhibitor The report ...
January 2022
60 pages
Insulin Like Growth Factor 1 (IGF-1) Activators - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Insulin Like Growth Factor 1 (IGF-1) Activators The ...
January 2022
60 pages
Integrase Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Integrase Inhibitor The report assesses ...
January 2022
60 pages
Integrin Alpha 4beta1/Very Late Antigen-4 (VLA-4) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Integrin Alpha 4beta1/Very Late Antigen-4 (VLA-4) Inhibitor The ...
January 2022
60 pages
interleukin Agonist - Pipeline Insight, 2022
US$ 2,000.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “interleukin Agonist The report assesses ...
January 2022
120 pages
Interleukin-1 (IL-1) Inhibitor - Pipeline Insight, 2022
US$ 2,000.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Interleukin-1 (IL-1) Inhibitor The report assesses ...
January 2022
120 pages
Interleukin-10 (IL-10) Receptor Agonist - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Interleukin-10 (IL-10) Receptor Agonist The report ...
January 2022
60 pages
Interleukin-12 (IL-12) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Interleukin-12 (IL-12) Inhibitor The report ...
January 2022
60 pages
Interleukin-13 (IL-13) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Interleukin-13 (IL-13) Inhibitor The report ...
January 2022
60 pages
Interleukin-17 (IL-17) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Interleukin-17 (IL-17) Inhibitor The report ...
January 2022
60 pages
Interleukin-18 (IL-18) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Interleukin-18 (IL-18) Inhibitor The report ...
January 2022
60 pages
Interleukin-2 (IL-2) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Interleukin-2 (IL-2) Inhibitor The report assesses ...
January 2022
60 pages
Interleukin-2 (IL-2) Receptor Agonist - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Interleukin-2 (IL-2) Receptor Agonist The report ...
January 2022
60 pages
Interleukin-23 (IL-23) Inhibitor - Pipeline Insight, 2022
US$ 1,500.00
... (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Interleukin-23 (IL-23) Inhibitor The report ...
January 2022
90 pages
Interleukin-4 (IL-4) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Interleukin-4 (IL-4) Inhibitor The report assesses ...
January 2022
60 pages
Interleukin-5 (IL-5) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Interleukin-5 (IL-5) Inhibitor The report assesses ...
January 2022
60 pages
Interleukin-8 (IL-8) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Interleukin-8 (IL-8) Inhibitor The report assesses ...
January 2022
60 pages
Ionotropic Glutamate Receptor Antagonists - Pipeline Insight, 2022
US$ 2,000.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Ionotropic Glutamate Receptor Antagonist The report ...
January 2022
100 pages
Isocitrate Dehydrogenase (IDH) inhibitors- Pipeline Insight, 2022
US$ 1,500.00
... limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Isocitrate Dehydrogenase (IDH1) Inhibitor The report ...
January 2022
60 pages
Janus Kinase (JAK) Inhibitors- Pipeline Insight, 2022
US$ 2,500.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Janus Kinase (JAK) Inhibitor The report assesses ...
January 2022
150 pages
Mayus Kinase 1 (JAK1) Inhibitor - Pipeline Insight, 2022
US$ 1,500.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Janus Kinase 1 (JAK1) Inhibitor The report assesses ...
January 2022
90 pages
Mayus Kinase 3 (JAK3) Inhibitor - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Janus Kinase 3 (JAK3) Inhibitor The report assesses ...
January 2022
60 pages
Kainate Receptor Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Kainate Receptor Antagonist The report assesses ...
January 2022
60 pages
Kallikrein Inhibitor - Pipeline Insight, 2022
US$ 1,500.00
... not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Kallikrein Inhibitor The report assesses ...
January 2022
60 pages
Kappa Antagonist - Pipeline Insight, 2022
US$ 1,250.00
... drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Kappa Antagonist The report assesses the active Kappa Antagonist ...
January 2022
60 pages
Kv1.3/1.5 Potassium Channel Blockers - Pipeline Insight, 2022
US$ 1,250.00
... but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Kv1.3/1.5 Potassium Channel Blockers The report ...
January 2022
60 pages
Kv1.3 Potassium Channel Blockers - Pipeline Insight, 2022
US$ 1,250.00
... (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for “Kv1.3 Potassium Channel Blockers The report ...
January 2022
60 pages
